The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ulthera.com

Total Raised

$38.56M

Investors Count

5

Deal Terms

4

Ulthera Funding, Ulthera Valuation & Ulthera Revenue

5 Fundings

Ulthera's latest funding round was a Acquired for on July 30, 2014.

Ulthera's valuation in February 2011 was $24.97M.

Ulthera's latest post-money valuation is from July 2014.

Sign up for a free trial to see Ulthera's valuations in July 2014, January 2008, December 2005 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

7/30/2014

Acquired

$99M

$0.00B

((9.99x))

FY 1234

2

2/1/2011

Series C

$99M

$24.97M

0

FY undefined

10

1/18/2008

Series B

$99M

$99M

0

FY undefined

0

12/12/2005

Series A

$99M

$99M

0

FY undefined

0

Other Investors

0

FY undefined

0

Date

7/30/2014

2/1/2011

1/18/2008

12/12/2005

Round

Acquired

Series C

Series B

Series A

Other Investors

Amount

$99M

$99M

$99M

Investors

Valuation

$99M

$24.97M

$99M

$99M

Revenue

$0.00B

((9.99x))

FY 1234

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

2

10

0

0

0

Ulthera Deal Terms

4 Deal Terms

Ulthera's deal structure is available for 4 funding rounds, including their Acquired from July 30, 2014.

Round

Acquired

Series C

Series B

Series A

Funding Date

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

$99M

$99M

Post-Money Valuation

$99M

$99M

$99M

$99M

Amount Raised

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

General Voting

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Ulthera Investors

5 Investors

Ulthera has 5 investors. Merz Therapeutics invested in Ulthera's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

7/30/2014

7/30/2014

1
Acquired

Corporation

Germany

00/00/0000

00/00/0000

New Enterprise Associates

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Apposite Capital

Subscribe to see more

Subscribe to see more

Private Equity

United Kingdom

00/00/0000

00/00/0000

3i Group

Subscribe to see more

Subscribe to see more

Private Equity

United Kingdom

Ardent Sound

Subscribe to see more

Corporation

Arizona

First funding

7/30/2014

00/00/0000

00/00/0000

00/00/0000

Last Funding

7/30/2014

00/00/0000

00/00/0000

00/00/0000

Investor

New Enterprise Associates

Apposite Capital

3i Group

Ardent Sound

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Type

Corporation

Venture Capital

Private Equity

Private Equity

Corporation

Location

Germany

California

United Kingdom

United Kingdom

Arizona

Ulthera Acquisitions

1 Acquisition

Ulthera acquired 1 company. Their latest acquisition was Cabochon Aesthetics on March 21, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/21/2014

Debt

$99M

$14.78M

Acquired

1

Date

3/21/2014

Investment Stage

Debt

Companies

Valuation

$99M

Total Funding

$14.78M

Note

Acquired

Sources

1

You May Also Like

A
Affinergy

Affinergy develops site-specific biological delivery systems using biofriendly binders that can selectively adhere to proteins, cells and other biomaterial surfaces. Affinergy's multifunctional delivery systems offer unprecedented opportunities to target therapeutic delivery, functionalize medical devices, and enable a variety of diagnostic and biosensor applications. Affinergy is a Duke University spin-out company being incubated by BD (Becton, Dickinson and Company) and is headquartered in Research Triangle Park, NC. IDEA Fund Partners was an investor in the company's Series A financing.

Akonni Biosystems Logo
Akonni Biosystems

Akonni Biosystems is a molecular diagnostics (MDx) company that develops, manufactures, and markets integrated molecular diagnostic systems.

Q
QI2

UIQI2 is designed to develop and utilize in-house processes and technical infrastructure for the conduct of imaging-based multi-center trials. The main objective is to develop infrastructure within the University of Iowa, which will support the pulmonary imaging portion of government and industry-based multi-center trials. The target audience is government and corporate sponsored multi-centered pre-clinical and clinical trials; specifically the Pharmaceutical and Device sectors of the medical industry as well as large NIH trials.

I
Integrated Nano-Technologies

Integrated Nano-Technologies specializes in developing creative solutions for diagnostic sample processing, and provides field personnel with fast, accurate test results that can improve biological identification.

F
Focal

Focal develops, manufactures and commercializes synthetic, absorbable, liquid surgical sealants based on the company's polymer technology. The company's FocalSeal-L and FocalSeal-S surgical sealant products are currently being developed for use inside the body to seal leaks resulting from lung, neurological, cardiovascular and gastrointestinal surgery.

Sober Steering Logo
Sober Steering

Sober Steering develops transdermal technologies as means for detecting driver intoxication.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.